[go: up one dir, main page]

BE2014C017I2 - - Google Patents

Info

Publication number
BE2014C017I2
BE2014C017I2 BE2014C017C BE2014C017C BE2014C017I2 BE 2014C017 I2 BE2014C017 I2 BE 2014C017I2 BE 2014C017 C BE2014C017 C BE 2014C017C BE 2014C017 C BE2014C017 C BE 2014C017C BE 2014C017 I2 BE2014C017 I2 BE 2014C017I2
Authority
BE
Belgium
Application number
BE2014C017C
Other languages
French (fr)
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=15924444&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2014C017(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of BE2014C017I2 publication Critical patent/BE2014C017I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BE2014C017C 1999-06-17 2014-03-04 BE2014C017I2 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP17150999 1999-06-17

Publications (1)

Publication Number Publication Date
BE2014C017I2 true BE2014C017I2 (no) 2019-05-21

Family

ID=15924444

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2014C017C BE2014C017I2 (no) 1999-06-17 2014-03-04

Country Status (26)

Country Link
US (11) US6462058B1 (no)
EP (3) EP2343289A1 (no)
KR (3) KR100407847B1 (no)
CN (1) CN1150186C (no)
AR (5) AR031069A1 (no)
AT (1) ATE391126T1 (no)
AU (1) AU778820B2 (no)
BE (1) BE2014C017I2 (no)
BR (1) BRPI0011674B8 (no)
CA (1) CA2375201C (no)
CY (2) CY1110384T1 (no)
DE (1) DE60038481T2 (no)
DK (2) DK1977751T3 (no)
ES (2) ES2426985T3 (no)
HU (1) HU229067B1 (no)
IL (2) IL145996A0 (no)
MX (1) MXPA01012642A (no)
MY (1) MY125399A (no)
NO (1) NO321168B1 (no)
NZ (1) NZ515702A (no)
PL (1) PL201068B1 (no)
PT (2) PT1129088E (no)
SI (1) SI1129088T1 (no)
TW (2) TWI289557B (no)
WO (2) WO2000078745A2 (no)
ZA (1) ZA200108331B (no)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US20040224989A1 (en) * 1999-01-29 2004-11-11 Barberich Timothy J. S-lansoprazole compositions and methods
TWI289557B (en) * 1999-06-17 2007-11-11 Takeda Chemical Industries Ltd A crystal of a hydrate of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
AU5705700A (en) * 1999-06-30 2001-01-22 Takeda Chemical Industries Ltd. Crystals of benzimidazole compounds
CA2407208C (en) 2000-04-28 2010-08-17 Takeda Chemical Industries, Ltd. Process for producing optically active sulfoxide derivative
EP2281821B1 (en) * 2000-05-15 2014-10-22 Takeda Pharmaceutical Company Limited Process for producing a crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]benzimidazole
WO2002012225A1 (fr) 2000-08-04 2002-02-14 Takeda Chemical Industries, Ltd. Sels de composé à base de benzimidazole et leurs applications
DK1337525T3 (da) * 2000-12-01 2011-09-19 Takeda Pharmaceutical Fremgangsmåde til krystallisering af (R)- eller (S)-lansoprazol
DK2258351T3 (da) 2001-10-17 2013-08-26 Takeda Pharmaceutical Granula indeholdende lansoprazol i stor mængde
KR100467100B1 (ko) * 2002-03-20 2005-01-24 일양약품주식회사 2-[(4-메톡시-3-메틸)-2-피리디닐]메틸설피닐-5-(1Ｈ-피롤-1-릴)-1Ｈ-벤즈이미다졸 또는 이의 Ｎа염을 함유하는주사제의 제조방법
PL373539A1 (en) * 2002-03-27 2005-09-05 Teva Pharmaceutical Industries Ltd. Lansoprazole polymorphs and processes for preparation thereof
CA2502219C (en) 2002-10-16 2012-05-29 Takeda Pharmaceutical Company Limited A process for producing an amorphous isomer of lansoprazole
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
US20050220870A1 (en) * 2003-02-20 2005-10-06 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
CN100364987C (zh) 2003-03-24 2008-01-30 卫材R&D管理有限公司 亚砜衍生物或其盐的非定形态的制备方法
CA2529255A1 (en) * 2003-06-20 2004-12-29 Ch Chemicals (Pty) Ltd Polyurethane-based cementitious liner
AU2004257864A1 (en) * 2003-07-18 2005-01-27 Santarus, Inc. Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20050037070A1 (en) * 2003-07-18 2005-02-17 Santarus, Inc. Pharmaceutical formulatins useful for inhibiting acid secretion and methods for making and using them
US20070292498A1 (en) * 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
JP2007522217A (ja) * 2004-02-10 2007-08-09 サンタラス インコーポレイティッド プロトンポンプ阻害剤、緩衝剤および非ステロイド系抗炎症薬の組み合わせ
JP2007532677A (ja) * 2004-04-16 2007-11-15 サンタラス インコーポレイティッド プロトンポンプ阻害剤、緩衝剤、および運動促進薬の組み合わせ
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8461187B2 (en) 2004-06-16 2013-06-11 Takeda Pharmaceuticals U.S.A., Inc. Multiple PPI dosage form
WO2006030936A1 (ja) 2004-09-13 2006-03-23 Takeda Pharmaceutical Company Limited 酸化化合物の製造方法及び製造装置
CA2599340C (en) 2005-02-25 2012-12-04 Takeda Pharmaceutical Company Limited Method for producing granules
ES2259269B1 (es) 2005-03-03 2007-11-01 Esteve Quimica, S.A. Procedimiento para la preparacion de derivados de 2-(2-piridilmetilsulfinil)-bencimidazol opticamente activos.
EP1934201A1 (en) * 2005-10-06 2008-06-25 Auspex Pharmaceuticals Inc. Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties
KR20080081071A (ko) 2005-12-28 2008-09-05 다케다 야쿠힌 고교 가부시키가이샤 방출 제어 고형 제제
KR100758600B1 (ko) 2006-01-05 2007-09-13 주식회사 대웅제약 란소프라졸 결정형 ａ의 제조방법
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
US20100093804A1 (en) * 2006-12-07 2010-04-15 Hetero Drugs Limited novel crystalline form of lansoprazole
JP5366558B2 (ja) 2006-12-28 2013-12-11 武田薬品工業株式会社 口腔内崩壊性固形製剤
KR20150084013A (ko) * 2007-10-12 2015-07-21 다케다 파마슈티칼스 유에스에이, 인코포레이티드 음식 섭취와 관계없이 위장 장애를 치료하는 방법
US20100280077A1 (en) * 2007-12-18 2010-11-04 Watson Pharma Private Limited Process for Preparation of Stable Amorphous R-Lansoprazole
EP2573082A1 (en) * 2007-12-31 2013-03-27 Takeda Pharmaceutical Company Limited Crystalline solvated forms of (r)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1h-benzimidazole
UA103189C2 (ru) * 2008-03-10 2013-09-25 Такеда Фармасьютикал Компани Лимитед Кристаллическая форма бензимидазольного соединения
BRPI0909439A2 (pt) * 2008-03-11 2015-12-15 Takeda Pharmaceutical preparação sólida de desintegração oral, e, método para suprimir a ruptura de grânulos finos
CA2717578A1 (en) * 2008-03-18 2009-09-24 Dr. Reddy's Laboratories Ltd. Dexlansoprazole process and polymorphs
US20090263475A1 (en) * 2008-04-21 2009-10-22 Nagaraju Manne Dexlansoprazole compositions
EP2303868A2 (en) 2008-05-14 2011-04-06 Watson Pharma Private Limited Stable r(+)-lansoprazole amine salt and a process for preparing the same
PE20140977A1 (es) * 2008-07-28 2014-08-20 Takeda Pharmaceutical Composicion farmaceutica estabilizada a base de un compuesto no peptidico
US20100113527A1 (en) * 2008-09-30 2010-05-06 Teva Pharmaceutical Industries Ltd. Crystalline forms of dexlansoprazole
IT1391758B1 (it) * 2008-11-11 2012-01-27 Dipharma Francis Srl Procedimento per la preparazione di dexlansoprazolo amorfo
KR101321055B1 (ko) * 2008-11-14 2013-10-23 한미사이언스 주식회사 덱스란소프라졸의 신규 결정형 및 이를 포함하는 약학 조성물
IT1391776B1 (it) * 2008-11-18 2012-01-27 Dipharma Francis Srl Procedimento per la preparazione di dexlansoprazolo
IT1392813B1 (it) * 2009-02-06 2012-03-23 Dipharma Francis Srl Forme cristalline di dexlansoprazolo
US20110009637A1 (en) * 2009-02-10 2011-01-13 Dario Braga Crystals of Dexlansoprazole
WO2011004387A2 (en) * 2009-06-18 2011-01-13 Matrix Laboratories Ltd Process for the preparation of dexlansoprazole polymorphic forms
IT1395118B1 (it) * 2009-07-29 2012-09-05 Dipharma Francis Srl Procedimento per la preparazione di dexlansoprazolo cristallino
CN108383804A (zh) 2009-11-12 2018-08-10 特罗菲克斯制药股份有限公司 神经营养蛋白模拟化合物及其盐的晶型
US10273219B2 (en) 2009-11-12 2019-04-30 Pharmatrophix, Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
CN102108076B (zh) * 2009-12-23 2014-07-23 江苏豪森医药集团有限公司 制备无定形右兰索拉唑的方法
EP2528912A1 (en) 2010-01-29 2012-12-05 Ranbaxy Laboratories Limited Process for the preparation of crystalline forms of dexlansoprazole
US20110189271A1 (en) * 2010-02-02 2011-08-04 Vishal Lad Pharmaceutical formulations of acid-labile drugs
AU2011234003B2 (en) * 2010-03-31 2013-09-19 Sun Pharmaceutical Industries Limited Process for the preparation of dexlansoprazole
WO2011121546A1 (en) 2010-03-31 2011-10-06 Ranbaxy Laboratories Limited Salts of dexlansoprazole and their preparation
EP2384746A3 (en) 2010-05-05 2012-03-07 Sanovel Ilac Sanayi ve Ticaret A.S. Dual release oral tablet compositions of dexlansoprazole
EP2384747A3 (en) 2010-05-05 2012-01-18 Sanovel Ilac Sanayi ve Ticaret A.S. Oral Tablet Compositions Of Dexlansoprazole
EP2384745A3 (en) 2010-05-05 2012-01-18 Sanovel Ilac Sanayi ve Ticaret A.S. Modified release pharmaceutical compositions of dexlansoprazole
WO2012001705A2 (en) 2010-06-29 2012-01-05 Cadila Healthcare Limited Pharmaceutical compositions of (r)-lansoprazole
EP2647381A4 (en) 2010-12-03 2015-12-23 Takeda Pharmaceutical MELTING TABLET
PE20141115A1 (es) 2010-12-27 2014-09-12 Takeda Pharmaceutical Comprimido de desintegracion oral
WO2012095859A1 (en) * 2011-01-12 2012-07-19 Hetero Research Foundation Polymorphs of dexlansoprazole salts
WO2012104805A1 (en) 2011-02-01 2012-08-09 Ranbaxy Laboratories Limited Process for the preparation of dexlansoprazole
WO2012111024A1 (en) 2011-02-18 2012-08-23 Suven Nishtaa Pharma Pvt Ltd Pharmaceutical compositions of dexlansoprazole
AU2012274967A1 (en) * 2011-06-21 2014-01-23 Sun Pharmaceutical Industries Limited Process for the preparation of dexlansoprazole
CN102875530A (zh) * 2011-07-15 2013-01-16 上海睿智化学研究有限公司 一种(r)-兰索拉唑叔丁胺盐及其晶型和制备方法
CN102875532B (zh) * 2011-07-15 2015-05-13 上海睿智化学研究有限公司 一种(r)-兰索拉唑异丙胺盐及其晶型和制备方法
CN102875531B (zh) * 2011-07-15 2015-08-19 上海睿智化学研究有限公司 一种(r)-兰索拉唑无水晶型及其制备方法
CN102234265B (zh) * 2011-08-08 2013-11-20 天津市汉康医药生物技术有限公司 兰索拉唑化合物
TWI630002B (zh) 2011-11-30 2018-07-21 武田藥品工業股份有限公司 乾塗覆錠
UA112667C2 (uk) 2011-12-16 2016-10-10 Атопікс Терапеутікс Лімітед Комбінація антагоніста crth2 і інгібітору протонного насоса для лікування еозинофільного езофагіту
WO2013140120A1 (en) 2012-03-22 2013-09-26 Cipla Limited Glycerol solvate forms of (r) - 2 - [ [ [3 -methyl -4 (2,2, 2 - trifluoroethoxy) pyridin- 2 - yl] methyl] sulphinyl] - 1h - ben zimidazole
WO2013179194A1 (en) 2012-05-31 2013-12-05 Ranbaxy Laboratories Limited Process for the preparation of crystalline dexlansoprazole
CN103709139B (zh) * 2012-10-09 2016-12-21 上海汇伦生命科技有限公司 无水右兰索拉唑的制备方法
CN104177333A (zh) * 2013-05-24 2014-12-03 四川海思科制药有限公司 一种理化性质稳定的(r)-2-[[[3-甲基-4-(2,2,2-三氟乙氧基)-2-吡啶基]甲基]亚磺酰基]-1h-苯并咪唑
CN104650035A (zh) * 2013-11-25 2015-05-27 天津市汉康医药生物技术有限公司 右兰索拉唑倍半水合物化合物
CN103664889B (zh) * 2013-12-19 2014-11-19 悦康药业集团有限公司 一种兰索拉唑化合物
US10130618B2 (en) 2014-04-11 2018-11-20 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical combinations of dabigatran and proton pump inhibitors
WO2015155307A1 (en) 2014-04-11 2015-10-15 Sanovel Ilac Sanayi Ve Ticaret A.S. Pharmaceutical combinations of rivaroxaban and proton pump inhibitors
CN104844576B (zh) * 2015-04-28 2017-03-08 山东罗欣药业集团股份有限公司 一种兰索拉唑或右旋兰索拉唑晶型化合物及其制备方法
CN104829594A (zh) * 2015-05-15 2015-08-12 苗怡文 一种治疗胃溃疡的药物兰索拉唑化合物
CN105017218A (zh) * 2015-07-01 2015-11-04 合肥安德生制药有限公司 一种右兰索拉唑晶型及其制备方法
CN104958276A (zh) * 2015-07-30 2015-10-07 青岛蓝盛洋医药生物科技有限责任公司 一种治疗胃溃疡的药物兰索拉唑组合物胶囊
CN104997738A (zh) * 2015-08-10 2015-10-28 青岛蓝盛洋医药生物科技有限责任公司 一种治疗胃病的药物兰索拉唑组合物干混悬剂
CN105399728B (zh) * 2015-12-20 2017-11-28 寿光富康制药有限公司 一种适用于工业化生产的右兰索拉唑的处理方法
CN108164507A (zh) * 2016-12-07 2018-06-15 天津药物研究院有限公司 一种右兰索拉唑单晶及其制备方法和用途
TR201701461A2 (tr) 2017-01-31 2018-08-27 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dekslansoprazolün Enterik Kaplı Farmasötik Kompozisyonları
CN106866630B (zh) * 2017-04-01 2018-08-07 上海华源医药科技发展有限公司 一种右兰索拉唑的制备方法
CN107011329A (zh) * 2017-05-05 2017-08-04 广州大光制药有限公司 兰索拉唑一水合物晶型及其结晶制备方法
CN108794450B (zh) * 2018-07-24 2022-08-19 浙江恒康药业股份有限公司 制备无定型右旋兰索拉唑的方法
WO2024075017A1 (en) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition of aortic valve calcification

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
DK171989B1 (da) 1987-08-04 1997-09-08 Takeda Chemical Industries Ltd Fremgangsmåde til fremstilling af 2-(2-pyridylmethylsulfinyl)-benzimidazoler
DE4035455A1 (de) 1990-11-08 1992-05-14 Byk Gulden Lomberg Chem Fab Enantiomerentrennung
SE504459C2 (sv) 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
GB9423968D0 (en) * 1994-11-28 1995-01-11 Astra Ab Resolution
HRP960232A2 (en) 1995-07-03 1998-02-28 Astra Ab A process for the optical purification of compounds
US5840737A (en) * 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
AU5652698A (en) 1996-11-12 1998-06-03 Byk Gulden Lomberg Chemische Fabrik Gmbh (2,3-dihydrobenzofuranyl)-thiazoles as phosphodiesterase inhibitors
TW385306B (en) * 1996-11-14 2000-03-21 Takeda Chemical Industries Ltd Method for producing crystals of benzimidazole derivatives
TR199901101T2 (xx) * 1996-11-22 1999-07-21 The Procter & Gamble Company Gastroenstentinal hastal�klar�n tedavisine y�nelik bizmut ve nsaid i�eren bile�imler.
SE510666C2 (sv) 1996-12-20 1999-06-14 Astra Ab Nya Kristallmodifikationer
AU742620B2 (en) 1998-01-30 2002-01-10 Sepracor, Inc. R-lansoprazole compositions and methods
WO1999038512A1 (en) 1998-01-30 1999-08-05 Sepracor Inc. S-lansoprazole compositions and methods
AU3596199A (en) * 1998-05-06 1999-11-23 Kobenhavns Universitet Treatment of celiac disease
TWI289557B (en) * 1999-06-17 2007-11-11 Takeda Chemical Industries Ltd A crystal of a hydrate of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
JP3283252B2 (ja) * 1999-06-17 2002-05-20 武田薬品工業株式会社 ベンズイミダゾール化合物の結晶
AU5705700A (en) * 1999-06-30 2001-01-22 Takeda Chemical Industries Ltd. Crystals of benzimidazole compounds
CN1117747C (zh) * 2000-06-19 2003-08-13 中国科学院成都有机化学研究所 光学纯兰索拉唑的制备方法
CA2502219C (en) * 2002-10-16 2012-05-29 Takeda Pharmaceutical Company Limited A process for producing an amorphous isomer of lansoprazole
CN100364987C (zh) * 2003-03-24 2008-01-30 卫材R&D管理有限公司 亚砜衍生物或其盐的非定形态的制备方法
RU2007123436A (ru) * 2004-12-20 2009-01-27 Др. Редди` Лабораторис Лтд. (IN) Фармацевтическая композиция, содержащая аморфные соединения бензимидазола, и способ ее приготовления
US8658216B2 (en) * 2004-12-23 2014-02-25 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions and process of preparation thereof
US20060210637A1 (en) * 2005-03-17 2006-09-21 Qpharma, Llc Stable tablet dosage forms of proton pump inhibitors
US20100280077A1 (en) * 2007-12-18 2010-11-04 Watson Pharma Private Limited Process for Preparation of Stable Amorphous R-Lansoprazole

Also Published As

Publication number Publication date
AR093609A2 (es) 2015-06-10
HU229067B1 (en) 2013-07-29
US20030045724A1 (en) 2003-03-06
PL201068B1 (pl) 2009-03-31
HK1123985A1 (en) 2009-07-03
US8552198B2 (en) 2013-10-08
EP2343289A1 (en) 2011-07-13
KR100407847B1 (ko) 2003-12-01
US20050228026A1 (en) 2005-10-13
CA2375201C (en) 2010-02-09
CY1114485T1 (el) 2017-01-25
PT1977751E (pt) 2013-08-01
EP1977751A1 (en) 2008-10-08
KR20010052467A (ko) 2001-06-25
US6939971B2 (en) 2005-09-06
ZA200108331B (en) 2002-10-10
US8884019B2 (en) 2014-11-11
US20080132547A1 (en) 2008-06-05
AU5247800A (en) 2001-01-09
CN1355798A (zh) 2002-06-26
AU778820B2 (en) 2004-12-23
MY125399A (en) 2006-07-31
AR100473A2 (es) 2016-10-12
EP1129088A2 (en) 2001-09-05
KR20010071354A (ko) 2001-07-28
US7339064B2 (en) 2008-03-04
HUP0201659A3 (en) 2003-11-28
ES2426985T3 (es) 2013-10-28
CA2375201A1 (en) 2000-12-28
US20100222391A1 (en) 2010-09-02
DK1977751T3 (da) 2013-09-02
HUP0201659A2 (hu) 2002-11-28
US20150025115A1 (en) 2015-01-22
SI1129088T1 (sl) 2008-08-31
PL352193A1 (en) 2003-08-11
NO20016087D0 (no) 2001-12-13
CY1110384T1 (el) 2015-04-29
MXPA01012642A (es) 2002-07-22
HK1038227A1 (en) 2002-03-08
KR100537029B1 (ko) 2005-12-16
BRPI0011674B1 (pt) 2017-05-30
AR079473A2 (es) 2012-01-25
ATE391126T1 (de) 2008-04-15
US20040048898A1 (en) 2004-03-11
TWI275587B (en) 2007-03-11
US6462058B1 (en) 2002-10-08
NO20016087L (no) 2001-12-13
NO321168B1 (no) 2006-03-27
ES2300265T3 (es) 2008-06-16
WO2004083200A1 (en) 2004-09-30
US20140012006A1 (en) 2014-01-09
WO2000078745A3 (en) 2001-07-05
IL145996A0 (en) 2002-07-25
US9145389B2 (en) 2015-09-29
PT1129088E (pt) 2008-05-05
BRPI0011674B8 (pt) 2021-05-25
EP1977751B1 (en) 2013-07-24
AR103295A2 (es) 2017-05-03
BR0011674A (pt) 2002-03-19
US7737282B2 (en) 2010-06-15
AR031069A1 (es) 2003-09-10
KR20030068592A (ko) 2003-08-21
NZ515702A (en) 2003-07-25
CN1150186C (zh) 2004-05-19
DK1129088T3 (da) 2008-06-09
DE60038481D1 (de) 2008-05-15
DE60038481T2 (de) 2009-04-09
US20120316344A1 (en) 2012-12-13
US20110319450A1 (en) 2011-12-29
TWI289557B (en) 2007-11-11
US20090163553A1 (en) 2009-06-25
WO2000078745A2 (en) 2000-12-28
IL145996A (en) 2008-07-08
US8030333B2 (en) 2011-10-04
EP1129088B1 (en) 2008-04-02
US7569697B2 (en) 2009-08-04
KR100514204B1 (ko) 2005-09-13
US6664276B2 (en) 2003-12-16

Similar Documents

Publication Publication Date Title
BE2018C020I2 (no)
BE2016C007I2 (no)
BE2015C057I2 (no)
BE2015C018I2 (no)
BE2014C017I2 (no)
BE2013C051I2 (no)
BE2013C020I2 (no)
BE2013C015I2 (no)
BE2013C001I2 (no)
BE2012C036I2 (no)
BE2011C004I2 (no)
JP2002513255A5 (no)
JP2002509768A5 (no)
JP2002516704A5 (no)
JP2002520689A5 (no)
JP2002517853A5 (no)
JP2002512493A5 (no)
JP2002510150A5 (no)
BRPI0001672A2 (no)
JP2002525687A5 (no)
JP2002524298A5 (no)
JP2002514478A5 (no)
JP2002522942A5 (no)
BRPI0001542A2 (no)
JP2002503033A5 (no)